A TUMOR GROWTH INHIBITION-OVERALL SURVIVAL MODEL FOR ATEZOLIZUMAB IN FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER BASED ON INTERIM DATA FROM THE IMPASSION130 STUDY.

Chan H.; Marchand M.; Wu B.; Vadhavkar S.; Chui S.; Claret L.; Bruno R.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >A TUMOR GROWTH INHIBITION-OVERALL SURVIVAL MODEL FOR ATEZOLIZUMAB IN FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER BASED ON INTERIM DATA FROM THE IMPASSION130 STUDY.

【24h】

A TUMOR GROWTH INHIBITION-OVERALL SURVIVAL MODEL FOR ATEZOLIZUMAB IN FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER BASED ON INTERIM DATA FROM THE IMPASSION130 STUDY.

机译：基于IMPASSION130研究的临时数据，肿瘤生长抑制 - 熟唑珠单抗中的七分转移性三重阴性乳腺癌。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics 》 |2020年第s1期| 共1页
作者
Chan H.; Marchand M.; Wu B.; Vadhavkar S.; Chui S.; Claret L.; Bruno R.;
展开▼
作者单位

Genentech Inc San Francisco CA 94080 USA;

Certara Marseille France;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Roche Marseille France;

Genentech Roche Marseille France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学 ;
关键词

相似文献

外文文献
中文文献
专利

1. A TUMOR GROWTH INHIBITION-OVERALL SURVIVAL MODEL FOR ATEZOLIZUMAB IN FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER BASED ON INTERIM DATA FROM THE IMPASSION130 STUDY. [J] . Chan H., Marchand M., Wu B., Clinical Pharmacology and Therapeutics . 2020 ,第S1期

机译：基于IMPASSION130研究的临时数据，肿瘤生长抑制 - 熟唑珠单抗中的七分转移性三重阴性乳腺癌。
2. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2020 ,第5期

机译：患者报告的atezolizumab Plus Nab-Paclitaxel在转移性三阴性乳腺癌中的试验结果
3. Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study [J] . Claret Laurent, Pentafragka Christina, Karovic Sanja, Cancer chemotherapy and pharmacology. . 2018 ,第1期

机译：肿瘤生长抑制 - 整体存活模型的肿瘤大小评估与丝绒研究中的二线结直肠癌数据的比较
4. Simulating an Immune Response with a Combined Agent-Based Model of a Triple-Negative Breast Cancer Tumor and Vascular Network [C] . Michael Ventoso, Kerri-Ann Norton IEEE International Conference on Bioinformatics and Biomedicine . 2020

机译：用三重阴性乳腺癌肿瘤和血管网络的基于组合药物的免疫应答模拟免疫应答
5. Regulation and action of SKP2 and RhoA in cell and tumor models: Investigation into the molecular mechanisms responsible for the aggressive phenotype of triple-negative breast cancer. [D] . Fagan-Solis, Katerina D. 2013

机译：在细胞和肿瘤模型中SKP2和RhoA的调控和作用：调查导致三阴性乳腺癌的侵袭性表型的分子机制。
6. A poxviral-based cancer vaccine targeting the transcription factor Twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model [O] . Anna R. Kwilas, Andressa Ardiani, Ulrike Dirmeier, 2015

机译：靶向转录因子Twist的基于痘病毒的癌症疫苗可抑制转移性乳腺癌模型中的原发性肿瘤生长和转移并改善自发性前列腺癌模型中的生存率
7. ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer [O] . Peter Schmid 2018

机译：ESMO 2018总统研讨会 - Impassion130：atezolizumab + Nab-Paclitaxel在三阴性乳腺癌中
8. Novel Differentiation Therapy Approach to Reduce the Metastatic Potential of Basal, Highly Metastatic, Triple-Negative Breast Cancers. [R] . Chu, I. 2012

机译：新型分化治疗方法降低基底，高转移性，三阴性乳腺癌的转移潜能。

A TUMOR GROWTH INHIBITION-OVERALL SURVIVAL MODEL FOR ATEZOLIZUMAB IN FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER BASED ON INTERIM DATA FROM THE IMPASSION130 STUDY.

著录项

相似文献

相关主题

期刊订阅